Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
Resveratrol187 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A15688 | 28759727 | Can J Physiol Pharmacol | The beneficial effects of resveratrol on steatosis and mitochondrial oxidative stress in HepG2 cells. | 2017 | Details |
| A15819 | 28694655 | World J Gastroenterol | Antioxidant dietary approach in treatment of fatty liver: New insights and updates. | 2017 | Details |
| A16337 | 28449683 | Lipids Health Dis | Inhibition of NAMPT aggravates high fat diet-induced hepatic steatosis in mice through regulating Sirt1/AMPKα/SREBP1 signaling pathway. | 2017 | Details |
| A16432 | 28393690 | Curr Med Chem | Hepatic AMP Kinase as a Potential Target for Treating Nonalcoholic Fatty Liver Disease: Evidence from Studies of Natural Products. | 2018 | Details |
| A16463 | 28373762 | World J Gastroenterol | Traditional Chinese herbal extracts inducing autophagy as a novel approach in therapy of nonalcoholic fatty liver disease. | 2017 | Details |
| A16523 | 28338115 | J Gastrointestin Liver Dis | Resveratrol Supplementation in Patients with Non-Alcoholic Fatty Liver Disease: Systematic Review and Meta-analysis. | 2017 | Details |
| A16560 | 28317281 | Mol Nutr Food Res | Comparison of dietary polyphenols for protection against molecular mechanisms underlying nonalcoholic fatty liver disease in a cell model of steatosis. | 2017 | Details |
| A16825 | 28146130 | Nutrients | Effects of Natural Products on Fructose-Induced Nonalcoholic Fatty Liver Disease (NAFLD). | 2017 | Details |
| A16939 | 28082803 | World J Gastroenterol | Liver fibrosis and hepatic stellate cells: Etiology, pathological hallmarks and therapeutic targets. | 2016 | Details |
| A16984 | 28063505 | Nutrition | Alternative treatment methods attenuate the development of NAFLD: A review of resveratrol molecular mechanisms and clinical trials. | 2016 | Details |
| A17050 | 28028356 | World J Gastroenterol | Sirtuins and nonalcoholic fatty liver disease. | 2016 | Details |
| A17360 | 27824430 | Drug Res (Stuttg) | Dietary Fructose-Induced Hepatic Injury in Male and Female Rats: Influence of Resveratrol. | 2016 | Details |
| A17522 | 27757967 | J Pharm Pharmacol | Diet-induced non-alcoholic fatty liver disease affects expression of major cytochrome P450 genes in a mouse model. | 2016 | Details |
| A17766 | 27613163 | Mol Cell Biochem | Resveratrol supplement inhibited the NF-κB inflammation pathway through activating AMPKα-SIRT1 pathway in mice with fatty liver. | 2016 | Details |
| A17822 | 27560482 | PLoS One | Efficacy of Resveratrol Supplementation against Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Placebo-Controlled Clinical Trials. | 2016 | Details |
| A17840 | 27545758 | Clin Res Hepatol Gastroenterol | Non-alcoholic fatty liver disease and flavonoids: Current perspectives. | 2016 | Details |
| A18746 | 26973390 | World J Gastroenterol | Resveratrol and fenofibrate ameliorate fructose-induced nonalcoholic steatohepatitis by modulation of genes expression. | 2016 | Details |
| A18832 | 26912655 | J Biol Chem | Sirtuin 3 (SIRT3) Regulates α-Smooth Muscle Actin (α-SMA) Production through the Succinate Dehydrogenase-G Protein-coupled Receptor 91 (GPR91) Pathway in Hepatic Stellate Cells. | 2016 | Details |
| A18834 | 26911834 | Sci Rep | Resveratrol ameliorates fibrosis and inflammation in a mouse model of nonalcoholic steatohepatitis. | 2016 | Details |
| A19069 | 26784973 | Scand J Gastroenterol | Placebo-controlled, randomised clinical trial: high-dose resveratrol treatment for non-alcoholic fatty liver disease. | 2016 | Details |
| A19487 | 26525891 | Sci Rep | Inhibition of HMGB1 release via salvianolic acid B-mediated SIRT1 up-regulation protects rats against non-alcoholic fatty liver disease. | 2015 | Details |
| A19543 | 26498332 | Lipids Health Dis | Resveratrol ameliorates hepatic steatosis and inflammation in methionine/choline-deficient diet-induced steatohepatitis through regulating autophagy. | 2015 | Details |
| A19650 | 26436447 | Liver Int | Natural antioxidants for non-alcoholic fatty liver disease: molecular targets and clinical perspectives. | 2015 | Details |
| A19845 | 26312773 | J Gastroenterol Hepatol | Effect of resveratrol on experimental non-alcoholic fatty liver disease depends on severity of pathology and timing of treatment. | 2016 | Details |
| A19852 | 26305052 | Biochem Cell Biol | Proposed trial: safety and efficacy of resveratrol for the treatment of non-alcoholic fatty liver disease (NAFLD) and associated insulin resistance in adolescents who are overweight or obese adolescents - rationale and protocol. | 2015 | Details |
| A19878 | 26289505 | Niger J Clin Pract | Nonalcoholic fatty liver disease: Synopsis of current developments. | 2016 | Details |
| A19968 | 26234526 | Br J Nutr | The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study. | 2015 | Details |
| A20134 | 26134756 | Pharm Biol | Protective effect of ursodeoxycholic acid, resveratrol, and N-acetylcysteine on nonalcoholic fatty liver disease in rats. | 2015 | Details |
| A20266 | 26055348 | Nutr Res | Resveratrol prevents hepatic steatosis and endoplasmic reticulum stress and regulates the expression of genes involved in lipid metabolism, insulin resistance, and inflammation in rats. | 2015 | Details |
| A20271 | 26052378 | World J Hepatol | Oxidative stress: New insights on the association of non-alcoholic fatty liver disease and atherosclerosis. | 2015 | Details |
| A20297 | 26040363 | Nutr Hosp | Effect of the intake of liquids rich in polyphenols on blood pressure and fat liver deposition in rats submitted to high-fat diet. | 2015 | Details |
| A20466 | 25943029 | Mol Nutr Food Res | Resveratrol improves hepatic steatosis by inducing autophagy through the cAMP signaling pathway. | 2015 | Details |
| A20655 | 25827944 | J Physiol Biochem | Liver delipidating effect of a combination of resveratrol and quercetin in rats fed an obesogenic diet. | 2015 | Details |
| A20673 | 25814186 | Pharmacol Res | Effect of resveratrol on experimental non-alcoholic steatohepatitis. | 2015 | Details |
| A21012 | 25577300 | Dig Liver Dis | Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: a randomized controlled trial. | 2014 | Details |
| A21258 | 25451038 | Obesity (Silver Spring) | A dietary phytochemical blend prevents liver damage associated with adipose tissue mobilization in ovariectomized rats. | 2014 | Details |
| A21447 | 25311610 | Nutr Res | Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease. | 2014 | Details |
| A21663 | 25140191 | Nutr Metab (Lond) | Effects and mechanisms of resveratrol on the amelioration of oxidative stress and hepatic steatosis in KKAy mice. | 2014 | Details |
| A21877 | 24985011 | Nutrition | Resveratrol attenuates hepatic steatosis in high-fat fed mice by decreasing lipogenesis and inflammation. | 2013 | Details |
| A21913 | 24966607 | World J Gastroenterol | Effects of resveratrol and other polyphenols in hepatic steatosis. | 2014 | Details |
| A22123 | 24799987 | World J Hepatol | Effects of resveratrol in experimental and clinical non-alcoholic fatty liver disease. | 2014 | Details |
| A22256 | 24716162 | J Tradit Complement Med | Recent advances in the herbal treatment of non-alcoholic Fatty liver disease. | 2013 | Details |
| A22370 | 24633463 | Arch Pharm Res | Protective effect of resveratrol derivatives on high-fat diet induced fatty liver by activating AMP-activated protein kinase. | 2014 | Details |
| A22380 | 24629563 | Metabolism | Resveratrol ameliorates hepatic metaflammation and inhibits NLRP3 inflammasome activation. | 2014 | Details |
| A22432 | 24582567 | Clin Gastroenterol Hepatol | Resveratrol does not benefit patients with nonalcoholic fatty liver disease. | 2014 | Details |
| A22792 | 24302567 | Mol Nutr Food Res | Chemoprevention of nonalcoholic fatty liver disease by dietary natural compounds. | 2013 | Details |
| A23185 | 23978414 | Food Chem Toxicol | Resveratrol modulates autophagy and NF-κB activity in a murine model for treating non-alcoholic fatty liver disease. | 2013 | Details |
| A23379 | 23832548 | Hepatology | M2 Kupffer cells promote M1 Kupffer cell apoptosis: a protective mechanism against alcoholic and nonalcoholic fatty liver disease. | 2013 | Details |
| A23595 | 23651738 | Toxicol Appl Pharmacol | Resveratrol inhibits LXRα-dependent hepatic lipogenesis through novel antioxidant Sestrin2 gene induction. | 2013 | Details |
| A24200 | 23127599 | Food Chem Toxicol | Alleviative effects of resveratrol on nonalcoholic fatty liver disease are associated with up regulation of hepatic low density lipoprotein receptor and scavenger receptor class B type I gene expressions in rats. | 2012 | Details |
| A24244 | 23084643 | Nutr Res | Resveratrol up-regulates hepatic uncoupling protein 2 and prevents development of nonalcoholic fatty liver disease in rats fed a high-fat diet. | 2012 | Details |
| A24959 | 22311412 | Chin J Integr Med | Chinese herbal medicine in the treatment of nonalcoholic fatty liver disease. | 2012 | Details |
| A25189 | 22105311 | Eur J Nutr | Cardioprotective and hepatoprotective effects of ellagitannins from European oak bark (Quercus petraea L.) extract in rats. | 2011 | Details |
| A25543 | 21733326 | Br J Nutr | Resveratrol attenuates steatosis in obese Zucker rats by decreasing fatty acid availability and reducing oxidative stress. | 2011 | Details |
| A25699 | 21525818 | Med Sci Monit | SIRT1 as a potential therapeutic target for treatment of nonalcoholic fatty liver disease. | 2011 | Details |
| A26305 | 20673376 | Br J Nutr | A polyphenol extract modifies quantity but not quality of liver fatty acid content in high-fat-high-sucrose diet-fed rats: possible implication of the sirtuin pathway. | 2010 | Details |
| A27043 | 19285015 | Biochem Biophys Res Commun | Resveratrol inhibits the expression of SREBP1 in cell model of steatosis via Sirt1-FOXO1 signaling pathway. | 2009 | Details |
| A27273 | 18782455 | BMC Gastroenterol | Resveratrol inhibits nonalcoholic fatty liver disease in rats. | 2008 | Details |
| A27385 | 18501116 | Acta Pharmacol Sin | Resveratrol improves non-alcoholic fatty liver disease by activating AMP-activated protein kinase. | 2008 | Details |
| A28682 | 35137921 | Int J Mol Med | Resveratrol ameliorates nutritional steatohepatitis through the mmu‑miR‑599/PXR pathway. | 2022 | Details |
| A42297 | 34935193 | Fundam Clin Pharmacol | Hepatoprotective and therapeutic effects of resveratrol: A focus on anti-inflammatory and antioxidative activities. | 2022 | Details |
| A43460 | 31663469 | Curr Med Chem | Effects of Pterostilbene on Diabetes, Liver Steatosis and Serum Lipids. | 2021 | Details |
| A43560 | 31408938 | Molecules | Resveratrol Maintains Lipid Metabolism Homeostasis via One of the Mechanisms Associated with the Key Circadian Regulator Bmal1. | 2019 | Details |
| A43790 | 30879091 | Cell Mol Life Sci | Long non-coding RNAs are emerging targets of phytochemicals for cancer and other chronic diseases. | 2019 | Details |
| A44125 | 29656521 | Diabetes Obes Metab | Resveratrol effect on patients with non-alcoholic fatty liver disease: A matter of dose and treatment length. | 2018 | Details |
| A44941 | 26664429 | J Res Med Sci | Resveratrol and liver: A systematic review. | 2015 | Details |
| A45029 | 26382727 | Dig Liver Dis | Comment on "Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: A randomized controlled trial" by Shihui Chen et al. [Dig. Liver Dis. 2015;47:226-32]. | 2015 | Details |
| A45035 | 26364558 | Dig Liver Dis | Authors' reply to the comment on "Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: A randomized controlled trial" by Shihui Chen et al. [Dig. Liver Dis. 2015;47:226-32]. | 2015 | Details |
| A45048 | 26299475 | Pharmacol Res | Response to letter to the Editor: "Similarity between studies of dihydromyricetin and resveratrol for NAFLD". | 2015 | Details |
| A45192 | 25761756 | Hepatology | Novel role for carbohydrate responsive element binding protein in the control of ethanol metabolism and susceptibility to binge drinking. | 2015 | Details |
| A45193 | 25753820 | Hepatology | Obeticholic acid and resveratrol in nonalcoholic fatty liver disease: all that is gold does not glitter, not all those who wander are lost. | 2015 | Details |
| A45566 | 23855468 | Ann N Y Acad Sci | Resveratrol in metabolic health: an overview of the current evidence and perspectives. | 2013 | Details |
| A46333 | 19474719 | Curr Opin Clin Nutr Metab Care | Metabolic benefits from Sirt1 and Sirt1 activators. | 2009 | Details |
| A49543 | 35720958 | 3 Biotech | Amelioration of high-fat diet (HFD) + CCl4 induced NASH/NAFLD in CF-1 mice by activation of SIRT-1 using cinnamoyl sulfonamide hydroxamate derivatives: in-silico molecular modelling and in-vivo prediction. | 2022 | Details |
| A49746 | 35651514 | Front Nutr | Polydatin, A Glycoside of Resveratrol, Is Better Than Resveratrol in Alleviating Non-alcoholic Fatty Liver Disease in Mice Fed a High-Fructose Diet. | 2022 | Details |
| A49792 | 35636169 | Phytomedicine | Pharmacological effects of polydatin in the treatment of metabolic diseases: A review. | 2022 | Details |
| A49905 | 35602098 | Oxid Med Cell Longev | A Molecular Insight into the Role of Antioxidants in Nonalcoholic Fatty Liver Diseases. | 2022 | Details |
| A50062 | 35538431 | BMC Cardiovasc Disord | Effect of resveratrol supplementation on hepatic steatosis and cardiovascular indices in overweight subjects with type 2 diabetes: a double-blind, randomized controlled trial. | 2022 | Details |
| A50966 | 35548751 | RSC Adv | Therapeutic efficacy of polydatin for nonalcoholic fatty liver disease via regulating inflammatory response in obese mice. | 2018 | Details |
| A51669 | 35070060 | World J Diabetes | Gut microbiota-derived metabolites are novel targets for improving insulin resistance. | 2022 | Details |
| A51951 | 32968453 | Oncol Lett | Identification of diagnostic and prognostic biomarkers, and candidate targeted agents for hepatitis B virus-associated early stage hepatocellular carcinoma based on RNA-sequencing data. | 2020 | Details |
| A52031 | 32125846 | J Agric Food Chem | Chemistry of Pterostilbene and Its Metabolic Effects. | 2020 | Details |
| A52039 | 32003501 | FASEB J | Resveratrol promotes white adipocytes browning and improves metabolic disorders in Sirt1-dependent manner in mice. | 2020 | Details |
| A52275 | 29402742 | Bioorg Med Chem Lett | Novel SIRT1 activator MHY2233 improves glucose tolerance and reduces hepatic lipid accumulation in db/db mice. | 2018 | Details |
| A52632 | 24473532 | Menopause | Resveratrol- and melatonin-abated ovariectomy and fructose diet-induced obesity and metabolic alterations in female rats. | 2014 | Details |
| A52650 | 24184811 | Gastroenterology | Hepatic SIRT1 attenuates hepatic steatosis and controls energy balance in mice by inducing fibroblast growth factor 21. | 2013 | Details |
| A52955 | 18930334 | J Hepatol | Dietary resveratrol alters lipid metabolism-related gene expression of mice on an atherogenic diet. | 2008 | Details |